CSF Biomarker-based Cognitive Trajectories in Parkinson’s Disease-Subjective Cognitive Decline
Objective: To investigate associations between CSF biomarkers and cognitive decline in Parkinson’s Disease-Subjective Cognitive Decline (PD-SCD). Background: The presence of cognitive complaints without objective cognitive…Expanding the Spectrum of Alzheimer’s Disease Clinical Presentations: Progressive Dysarthria with Monomelic Tremor
Objective: To present an unusual clinical presentation of an atypical Corticobasilar syndrome secondary to Alzheimer's disease. Background: Corticobasilar syndrome (CBS) typically presents with motor symptoms…Improving Diagnosis of Dementia in Parkinson’s Disease: PDCogniCare Australian Program
Objective: PDCogniCare program aims to improve the utility of cognitive evaluation for earlier and effective diagnosis of mild cognitive impairment and dementia in Parkinson's disease…Breaking Away From the Ivory Tower
Objective: We describe the evolution of the Geriatric Flying Squad (GFS), a rapid response outreach team for residential aged care facilities (RACFs) in the local…Prevalence, demographic characteristics of Parkinson disease and associated comorbidities: An analysis of the Colombian Ministry of Health official registry
Objective: Conduct a descriptive analysis of the Colombian Parkinson’s disease population and its comorbidities using data from the Colombian Ministry of Health.Estimate the prevalence and…Patient-derived α-synuclein seed amplification as a tool for evaluating small molecule aggregation inhibitors for Parkinson’s disease and Lewy Body Dementia therapeutics
Objective: To validate on-target engagement of disease-relevant ⍺-synuclein (a-syn) aggregates by WTX-607, WaveBreak’s small-molecule clinical candidate for Parkinson’s disease (PD) and Lewy body dementia (LBD),…The Movement Disorders Society Unified Parkinson Disease Rating Scale Motor Subscore Is Not Associated With Future Parkinson Disease Milestones – an observational study using linked health administrative data
Objective: To examine the association between time to Parkinson Disease (PD) health administrative data milestones and a one-year change in the Movement Disorders Society –…Plasma P-tau217 detects Alzheimer’s co-pathology and predicts cognitive decline in Parkinson’s disease
Objective: The objectives of this study are to compare plasma phosphorylated tau-217 (P-tau217) levels in Parkinson’s disease (PD) with versus without Alzheimer’s disease (AD) copathology…Multimodal Dissection of GALC Variants Linking Olfactory Deficits to Cognitive Decline in Parkinson’s Disease
Objective: Olfactory dysfunction is highly prevalent and often precedes motor symptoms, making it a potential early biomarker for disease progression and cognitive decline in Parkinson's…Metabolomics Profiling in Egyptian Patients with Alzheimer’s and Parkinson’s Diseases
Objective: To identify differential serum metabolites found in AD and PD patients and their correlations to clinical presentation in Egyptian patients. Background: There is a…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 36
- Next Page »